{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-011589","form_type":"8-K","ticker":"LPCN","cik":"0001535955","company_name":"Lipocine Inc.","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.268497+00:00","generated_at":"2026-05-17T20:39:09.734547+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Lipocine Q2 net loss narrows to $2.2M; Phase 3 PPD study underway","bullets":["Net loss of $2.2M ($0.41/diluted share) vs $3.1M loss year ago; cash $17.9M at quarter end.","LPCN 1154 Phase 3 pivotal trial for postpartum depression dosing patients; topline Q2 2026, NDA mid-2026.","LPCN 2401 Phase 2 proof-of-concept study in obesity planned, first patient dosing target Q3 2025.","TLANDO NDS filed in Canada by Verity Pharma in June; Brazil license deal with Aché in April.","Total revenue $623K (Q2) vs $90K year ago, including $500K license revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-011589","json":"https://secwatch.observer/filing/0001493152-25-011589.json","markdown":"https://secwatch.observer/filing/0001493152-25-011589.md","text":"https://secwatch.observer/filing/0001493152-25-011589.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225011589/0001493152-25-011589-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1535955/000149315225011589/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:39:09.734547+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}